PDF
Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants
Organization: Public Health Agency of Canada (PHAC)Published: 2022
"The purpose of this document is to update previous NACI recommendations for the use of PVZ, taking into consideration recent data on burden of illness due to RSV disease, the efficacy and effectiveness of PVZ in infants at risk of more severe RSV disease and economic implications of PVZ use." - Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants
Resource Group:
Implementation Tool
Product Type: Guide
Program Delivery and Evaluation
Guides
Monitoring and Surveillance
Outbreaks and Pandemics
Outbreaks
Product Type: Guide
Category:
Program Planning and Delivery,Program Delivery and Evaluation,Guides,Monitoring and Surveillance,Outbreaks and Pandemics,Outbreaks Program Planning and DeliveryProgram Delivery and Evaluation
Guides
Monitoring and Surveillance
Outbreaks and Pandemics
Outbreaks
Language:
English
LinkResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.